Pancreatic Cancer

A small-molecule CD73 inhibitor (AB680) induced a 41% overall response rate (ORR) when combined with chemotherapy (with nab-paclitaxel and gemcitabine), plus the novel PD-1 inhibitor zimberelimab, as a first-line treatment for patients with metastatic pancreatic cancer according to results of the dose-escalation portion of the phase 1/1b ARC-8 study. Read More ›

Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation
“The doublet is our recommendation for moving forward, and we believe these data define a reference regimen for germline BRCA-mutated, PALB2-mutated pancreas cancer,” said Eileen M. O’Reilly, MD. Read More ›

Pancreatic cancer is a difficult to treat malignancy with a high mortality rate. Patients are usually diagnosed with advanced disease, and many are not eligible for surgery. Although systemic therapy is a mainstay of treatment, there are limited options for patients with metastatic disease. We invite you to read more about some of the recent observational data on metastatic pancreatic cancer treatment patterns, patient outcomes, and costs in an effort to shed insights into real-world clinical decisions and the economic factors that influence them. Read More ›

Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
A claims analysis of elderly patients with pancreatic cancer has shown that those receiving early palliative care consultations had lower healthcare utilization, including emergency department-related costs, than patients who received late palliative care. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: